(Hong Kong, March 25, 2020) Desijia International Ophthalmology Limited ("Desijia", "Group" or "Company", SEHK: 1846.HK), the world's leading vision correction eye clinic group, released its annual results for the 12 months ended 31 December 2019 (the "reporting period"). During the reporting period, the group's performance was eye-catching, with a profit of about 49 million euros, an increase of 14% over the same period last year. Among them, the revenue of the German part is about 30 million euros, accounting for 61.7% of the total revenue; the income of the Danish part is about 5.8 million euros, accounting for 11.9% of the total revenue; and the income of Chinese clinics is about 13 million euros, accounting for 26.4% of the total revenue. The adjusted gross profit was about 20 million euros, an increase of 18.4% over the same period last year.
Desijia's main source of revenue is lens replacement surgery (including single-focus and trifocal lens replacement), which accounts for 46.8 per cent of the total revenue, accounting for about 23 million euros. Of these, the revenue from trifocal lens surgery is about 21 million euros, an annual increase of 33.3%. ICL implantation, with a revenue of about 6.7 million euros, remains one of the company's stable sources of revenue, accounting for 13.7% of the total revenue ratio for 2019.
The company's future prospect and development strategy
In order to promote the rapid and sustainable growth of the Group's business in the future, the company will continue to increase its influence and business coverage through foreign acquisitions, mergers and the opening of new clinics.
At present, the company is continuing to look for suitable eye clinic targets in Europe to continue to enhance the group's business influence and expand the geographical coverage of the company's vision correction services in Europe. In China, Desijia said it would continue the construction of its Chongqing clinic and Fuzhou clinic to expand its range of services to Chinese patients. At the same time, Desijia will continue to find suitable partners to open new clinics in other Chinese cities and join hands with strategic partners to enhance its influence in providing quality eye services around the world.
Launch new services and strive to be an industry pioneer in the implementation of new products and technologies
In 2020, Desijia will provide ophthalmic examination services for patients in China, especially fundus screening services for patients with diabetes. The service is expected to start in Shanghai clinics and gradually expand to the whole country. The ophthalmological examination service will help diabetic patients detect fundus abnormalities such as retinopathy at an early stage, so as to achieve the company's goal of "early screening, early detection and early treatment." This service will help the company to expand the patient base, increase the product service line, and provide more frequent services for patients. Desijia will work with large health examination centers, private hospitals and pharmaceutical companies in China to market and promote the service. At the same time, Desijia's doctors can detect other diseases (such as cataracts, macular degeneration and glaucoma) through eye examinations. the diagnosis and first-line treatment of these diseases can be completed in existing clinics in China.
In addition, Desijia will launch it to young presbyopia patients in Germany as soon as conditions permit.STAAR SurgicalThe super depth of field can be implanted with contact lenses ("EDOF ICL"). The new EDOF ICL will further establish the group's strong market position in the field of presbyopia treatment services and become an industry pioneer in the promotion of new products and technologies.
Provide better medical services for patients with new technology and equipment
Desijia will continue to look for new technologies to provide high-end care services for patients. The company has used Karl Zeiss Artevo 8003D digital microscope in Germany. Through this device, ophthalmologists can achieve extraordinary digital visualization during surgery, so that doctors can quickly and clearly identify the images needed for eye surgery.
At the same time, Desijia has begun to use the new Carl Zeiss OCT-AngioPlex in China to provide patients with non-invasive angiographic options. This technique makes it easier for doctors to detect abnormalities in the retina of patients with diabetes to help patients better prevent the deterioration of diabetic retinopathy and take the necessary treatment to reduce the risk of blindness.